Log in
Log in
E-mail
Password

Show password
Remember
Forgot password ?
Become a member for free
Sign up
Become a member for free
Sign up
New member
Sign up for FREE
New customer
Discover our services
  1. Homepage
  2. Equities
  3. United States
  4. Nyse
  5. Johnson & Johnson
  6. News
  7. Summary
    JNJ   US4781601046

JOHNSON & JOHNSON

(JNJ)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Johnson & Johnson : UBS Adjusts Price Target on Johnson & Johnson to $175 From $183 After Q3 Earnings Miss, Maintains Neutral Rating

10/21/2021 | 10:39am EDT
share with twitter
share with LinkedIn
share with facebook


© MT Newswires 2021
All news about JOHNSON & JOHNSON
05/26Legend Biotech Receives Conditional European Commission Approval for Multiple Myeloma D..
MT
05/25JOHNSON & JOHNSON : to Provide Webcast Fireside Chat on Clinical Data to be Presented at t..
PU
05/25Tentative $161.5M settlement reached in WVa opioid trial
AQ
05/25Janssen Presents Study Results Showing Clinical Efficacy for TREMFYA (guselkumab) and L..
AQ
05/25Nigeria Receives 4.4 Million Doses of Covid-19 Vaccines
AQ
05/24JOHNSON & JOHNSON : Janssen Presents Study Results Showing Clinical Efficacy for TREMFYA® ..
PU
05/24TRANSCRIPT : Johnson & Johnson Presents at UBS Global Healthcare Conference, May-24-2022 1..
CI
05/23Bayer's Xarelto Shows Long-Term Effect in Heart Disease Patients
MT
05/23JOHNSON & JOHNSON : New Data From Two Large Studies Reinforce Effectiveness of Dual Pathwa..
PU
05/23What We're Reading This Week
AQ
More news
Analyst Recommendations on JOHNSON & JOHNSON
More recommendations
Financials (USD)
Sales 2022 96 451 M - -
Net income 2022 23 016 M - -
Net cash 2022 8 885 M - -
P/E ratio 2022 20,3x
Yield 2022 2,46%
Capitalization 477 B 477 B -
EV / Sales 2022 4,85x
EV / Sales 2023 4,56x
Nbr of Employees 141 700
Free-Float 84,2%
Chart JOHNSON & JOHNSON
Duration : Period :
Johnson & Johnson Technical Analysis Chart | JNJ | US4781601046 | MarketScreener
Technical analysis trends JOHNSON & JOHNSON
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 17
Last Close Price 181,09 $
Average target price 187,75 $
Spread / Average Target 3,68%
EPS Revisions
Managers and Directors
Joaquin Duato Chief Executive Officer & Director
Joseph J. Wolk Chief Financial Officer & Executive Vice President
Matthew Stuckley Senior Financial Analyst-Janssen Commercial Pharm
Alex Gorsky Executive Chairman
Peter Shen Global Head-Research & Development
Sector and Competitors
1st jan.Capi. (M$)
JOHNSON & JOHNSON5.86%476 521
NOVO NORDISK A/S-3.80%1 677 391
PFIZER, INC.-8.70%302 483
ELI LILLY AND COMPANY17.11%291 184
ROCHE HOLDING AG-13.00%281 098
ABBVIE INC.10.78%265 067